[1] |
SCHNITZLER MA, SKEANS MA, AXELROD DA, et al. OPTN/SRTR 2016 annual data report: economics[J]. Am J Transplant, 2018, 18(Suppl 1): 464-503. DOI: 10.1111/ajt.14564.
|
[2] |
杨墨丹, 鲁迪, 陈俊丽, 等. 大数据时代背景下的中国肝移植质量提升[J/CD]. 实用器官移植电子杂志, 2020, 8(2): 93-95. DOI: 10.3969/j.issn.2095-5332.2020.02.004.YANG MD, LU D, CHEN JL, et al. Liver transplantation quality improvement in China in the era of big data[J/CD]. Pract J Organ Transplant (ElectrVers), 2020, 8(2): 93-95. DOI: 10.3969/j.issn.2095-5332.2020.02.004.
|
[3] |
LING Q, XU X, WANG B, et al. The origin of new-onset diabetes after liver transplantation: liver, islets, or gut?[J]. Transplantation, 2016, 100(4): 808-813. DOI: 10.1097/TP.0000000000001111.
|
[4] |
LING Q, XU X, XIE H, et al. New-onset diabetes after liver transplantation: a national report from China Liver Transplant Registry[J]. Liver Int, 2016, 36(5): 705-712. DOI: 10.1111/liv.13042.
|
[5] |
ROCCARO GA, GOLDBERG DS, HWANG WT, et al. Sustained posttransplantation diabetes is associated with long-term major cardiovascular events following liver transplantation[J]. Transplant, 2018, 18(1): 207-215. DOI: 10.1111/ajt.14401.
|
[6] |
RAMOS-PROL A, HERVÁS-MARÍN D, GARCÍA-CASTELL A, et al. Outcomes in patients with diabetes 10 years after liver transplantation[J]. J Diabetes, 2017, 9(11): 1033-1039. DOI: 10.1111/1753-0407.12520.
|
[7] |
LIEBER SR, LEE RA, JIANG Y, et al. The impact of post-transplant diabetes mellitus on liver transplant outcomes[J]. Clin Transplant, 2019, 33(6): e13554. DOI: 10.1111/ctr.13554.
|
[8] |
DAVIDSON J, WILKINSON A, DANTAL J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003[J]. Transplantation, 2003, 75(10 Suppl): SS3-SS24. DOI: 10.1097/01.TP.0000069952.49242.3E.
|
[9] |
SHARIF A, HECKING M, DE VRIES AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions[J]. Am J Transplant, 2014, 14(9): 1992-2000. DOI: 10.1111/ajt.12850.
|
[10] |
CHOWDHURY TA. Post-transplant diabetes mellitus[J]. Clin Med (Lond), 2019, 19(5): 392-395. DOI: 10.7861/clinmed.2019-0195.
|
[11] |
American Diabetes Association. Diagnosis and classification of diabetes mellitus[J]. Diabetes Care, 2014, 37(Suppl 1): S81-S90. DOI: 10.2337/dc14-S081.
|
[12] |
SHIVASWAMY V, BOERNER B, LARSEN J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes[J]. Endocr Rev, 2016, 37(1): 37-61. DOI: 10.1210/er.2015-1084.
|
[13] |
ZHANG T, LIU Y, HU Y, et al. Association of donor and recipient SUMO4 rs237025 genetic variant with new-onset diabetes mellitus after liver transplantation in a Chinese population[J]. Gene, 2017, 627: 428-433. DOI: 10.1016/j.gene.2017.06.060.
|
[14] |
GRANCINI V, RESI V, PALMIERI E, et al. Management of diabetes mellitus in patients undergoing liver transplantation[J]. Pharmacol Res, 2019, 141: 556-573. DOI: 10.1016/j.phrs.2019.01.042.
|
[15] |
PERACHA J, NATH J, READY A, et al. Risk of post-transplantation diabetes mellitus is greater in South Asian versus Caucasian kidney allograft recipients[J]. Transpl Int, 2016, 29(6): 727-739. DOI: 10.1111/tri.12782.
|
[16] |
TAN HL, LIM KB, IYER SG, et al. Metabolic syndrome after a liver transplantation in an Asian population[J]. HPB (Oxford), 2015, 17(8): 713-722. DOI: 10.1111/hpb.12435.
|
[17] |
VON DÜRING ME, JENSSEN T, BOLLERSLEV J, et al. Visceral fat is better related to impaired glucose metabolism than body mass index after kidney transplantation[J]. Transpl Int, 2015, 28(10): 1162-1171. DOI: 10.1111/tri.12606.
|
[18] |
ROCCARO GA, MITRANI R, HWANG WT, et al. Sustained virological response is associated with a decreased risk of posttransplant diabetes mellitus in liver transplant recipients with hepatitis C-related liver disease[J]. Liver Transpl, 2018, 24(12): 1665-1672. DOI: 10.1002/lt.25351.
|
[19] |
RUSSO FP, ZANETTO A, GAMBATO M, et al. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance[J]. J Viral Hepat, 2020, 27(2): 188-194. DOI: 10.1111/jvh.13215.
|
[20] |
LI DW, LU TF, HUA XW, et al. Risk factors for new onset diabetes mellitus after liver transplantation: a Meta-analysis[J]. World J Gastroenterol, 2015, 21(20): 6329-6340. DOI: 10.3748/wjg.v21.i20.6329.
|
[21] |
LIANG J, LV C, CHEN M, et al. Effects of preoperative hepatitis B virus infection, hepatitis C virus infection, and coinfection on the development of new-onset diabetes after kidney transplantation[J]. J Diabetes, 2019, 11(5): 370-378. DOI: 10.1111/1753-0407.12853.
|
[22] |
ORSI E, GRANCINI V, MENINI S, et al. Hepatogenous diabetes: is it time to separate it from type 2 diabetes?[J]. Liver Int, 2017, 37(7): 950-962. DOI: 10.1111/liv.13337.
|
[23] |
SEPEHRI Z, KIANI Z, AFSHARI M, et al. Inflammasomes and type 2 diabetes: an updated systematic review[J]. Immunol Lett, 2017, 192: 97-103. DOI: 10.1016/j.imlet.2017.10.010.
|
[24] |
IONUT V, CASTRO AV, WOOLCOTT OO, et al. Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia[J]. Am J Physiol Endocrinol Metab, 2014, 307(8): E644-E652. DOI: 10.1152/ajpendo.00244.2014.
|
[25] |
MÜLLER MM, SCHWAIGER E, KURNIKOWSKI A, et al. Glucose metabolism after kidney transplantation: insulin release and sensitivity with tacrolimus- versus belatacept-based immunosuppression[J]. Am J Kidney Dis, 2021, 77(3): 462-464. DOI: 10.1053/j.ajkd.2020.07.016.
|
[26] |
UME AC, WENEGIEME TY, WILLIAMS CR. Calcineurin inhibitors: a double-edged sword[J]. Am J Physiol Renal Physiol, 2021, 320(3): F336-F341. DOI: 10.1152/ajprenal.00262.2020.
|
[27] |
TRIÑANES J, RODRIGUEZ-RODRIGUEZ AE, BRITO-CASILLAS Y, et al. Deciphering tacrolimus-induced toxicity in pancreatic β cells[J]. Am J Transplant, 2017, 17(11): 2829-2840. DOI: 10.1111/ajt.14323.
|
[28] |
TORRES A, HERNÁNDEZ D, MORESO F, et al. Randomized controlled trial assessing the impact of tacrolimus versus cyclosporine on the incidence of posttransplant diabetes mellitus[J]. Kidney Int Rep, 2018, 3(6): 1304-1315. DOI: 10.1016/j.ekir.2018.07.009.
|
[29] |
CHEVALLIER E, JOUVE T, ROSTAING L, et al. pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression[J]. Expert Rev Clin Pharmacol, 2021, 14(1): 55-66. DOI: 10.1080/17512433.2021.1851596.
|
[30] |
BLAGOSKLONNY MV. Fasting and rapamycin: diabetes versus benevolent glucose intolerance[J]. Cell Death Dis, 2019, 10(8): 607. DOI: 10.1038/s41419-019-1822-8.
|
[31] |
BHAT V, TAZARI M, WATT KD, et al. New-onset diabetes and preexisting diabetes are associated with comparable reduction in long-term survival after liver transplant: a machine learning approach[J]. Mayo Clin Proc, 2018, 93(12): 1794-1802. DOI: 10.1016/j.mayocp.2018.06.020.
|
[32] |
JENSSEN T, HARTMANN A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15(3): 172-188. DOI: 10.1038/s41574-018-0137-7.
|
[33] |
LINDER KE, BAKER WL, ROCHON C, et al. Evaluation of posttransplantation diabetes mellitus after liver transplantation: assessment of insulin administration as a risk factor[J]. Ann Pharmacother, 2016, 50(5): 369-375. DOI: 10.1177/1060028015627662.
|
[34] |
LI Z, SUN F, HU Z, et al. New-onset diabetes mellitus in liver transplant recipients with hepatitis C: analysis of the national database[J]. Transplant Proc, 2016, 48(1): 138-144. DOI: 10.1016/j.transproceed.2015.11.010.
|
[35] |
XUE M, LV C, CHEN X, et al. Donor liver steatosis: a risk factor for early new-onset diabetes after liver transplantation[J]. J Diabetes Investig, 2017, 8(2): 181-187. DOI: 10.1111/jdi.12560.
|
[36] |
HARTOG H, MAY CJ, CORBETT C, et al. Early occurrence of new-onset diabetes after transplantation is related to type of liver graft and warm ischaemic injury[J]. Liver Int, 2015, 35(6): 1739-1747. DOI: 10.1111/liv.12706.
|
[37] |
中华医学会器官移植学分会. 中国移植后糖尿病诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(1): 1-9. DOI: 10.3969/j.issn.1674-7445.2019.01.001.Branch of Organ Transplantation of Chinese Medical Association. Technical specification for diagnosis and treatment of post transplantation diabetes mellitus in China (2019 edition)[J]. Organ Transplant, 2019, 10(1): 1-9. DOI: 10.3969/j.issn.1674-7445.2019.01.001.
|
[38] |
SHIMADA H, UCHIDA J, NISHIDE S, et al. Comparison of glucose tolerance between kidney transplant recipients and healthy controls[J]. J Clin Med, 2019, 8(7): 920. DOI: 10.3390/jcm8070920.
|
[39] |
HARE MJ, SHAW JE, ZIMMET PZ. Current controversies in the use of haemoglobin A1c[J]. J Intern Med, 2012, 271(3): 227-236. DOI: 10.1111/j.1365-2796.2012.02513.x.
|
[40] |
WISSING KM, ABRAMOWICZ D, WEEKERS L, et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation[J]. Am J Transplant, 2018, 18(7): 1726-1734. DOI: 10.1111/ajt.14665.
|
[41] |
CASTEDAL M, SKOGLUND C, AXELSON C, et al. Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation[J]. Scand J Gastroenterol, 2018, 53(6): 741-747. DOI: 10.1080/00365521.2018.1463390.
|
[42] |
MORGAN RD, O'CALLAGHAN JM, KNIGHT SR, et al. Alemtuzumab induction therapy in kidney transplantation: a systematic review and Meta-analysis[J]. Transplantation, 2012, 93(12): 1179-1788. DOI: 10.1097/TP.0b013e318257ad41.
|
[43] |
HECKING M, SHARIF A, ELLER K, et al. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics[J]. Transpl Int, 2021, 34(1): 27-48. DOI: 10.1111/tri.13783.
|
[44] |
LARSEN JL. Potential risks of metformin in transplant patients[J]. Am J Transplant, 2012, 12(3): 795-796. DOI: 10.1111/j.1600-6143.2011.03921.x.
|
[45] |
LO C, TOYAMA T, OSHIMA M, et al. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients[J]. Cochrane Database Syst Rev, 2020, 8: CD009966. DOI: 10.1002/14651858.CD009966.pub3.
|
[46] |
HALDEN TA, EGELAND EJ, ÅSBERG A, et al. GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes[J]. Diabetes Care, 2016, 39(4): 617-624. DOI: 10.2337/dc15-2383.
|
[47] |
ARODA VR. A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials[J]. Diabetes Obes Metab, 2018, 20(Suppl 1): 22-33. DOI: 10.1111/dom.13162.
|
[48] |
ALKINDI F, AL-OMARY HL, HUSSAIN Q, et al. Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients[J]. Transplant Proc, 2020, 52(1): 175-178. DOI: 10.1016/j.transproceed.2019.11.007.
|
[49] |
RAJASEKERAN H, KIM SJ, CARDELLA CJ, et al. Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series[J]. Diabetes Care, 2017, 40(7): e75-e76. DOI: 10.2337/dc17-0237.
|
[50] |
JIN J, JIN L, LUO K, et al. Effect of empagliflozin on tacrolimus-induced pancreas islet dysfunction and renal injury[J]. Am J Transplant, 2017, 17(10): 2601-2616. DOI: 10.1111/ajt.14316.
|
[51] |
ABDELAZIZ TS, ALI AY, FATTHY M. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus (PTDM)- a systematic review and Meta-analysis[J]. Curr Diabetes Rev, 2020, 16(6): 580-585. DOI: 10.2174/1573399815666190321144310.
|
[52] |
GAIFFE E, CREPIN T, BAMOULID J, et al. PRODIG (prevention of new onset diabetes after transplantation by a short term treatment of vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study[J]. Trials, 2019, 20(1): 375. DOI: 10.1186/s13063-019-3392-6.
|
[53] |
LEE M, SHIN E, BAE J, et al. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression[J]. Sci Rep, 2020, 10(1): 19429. DOI: 10.1038/s41598-020-75288-y.
|